QAX576
QAX576 is a pharmaceutical drug with 12 clinical trials. Historical success rate of 72.7%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
8
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
8 of 12 finished
33.3%
4 ended early
0
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
Clinical Trials (12)
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
Efficacy of QAX576 in Asthma
Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
SD, IL-13 Production Rate in IPF
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12